{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:20:20Z","timestamp":1792822820824,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The purpose of this article is to review the pharmacology, efficacy, and safety of the capsid inhibitor lenacapavir for the treatment of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A review of the literature was performed by searching PubMed\/MEDLINE for all relevant articles published between February 2021 and March 2023 using the keywords \u201clenacapavir,\u201d \u201cSunlenca,\u201d \u201chuman immunodeficiency virus,\u201d and \u201ctreatment\u201d together with \u201cmultidrug resistant human immunodeficiency virus.\u201d All English-language articles describing clinical trials assessing the efficacy and safety of lenacapavir when used in humans for the treatment of HIV infection were included. Review articles, conference abstracts, and article references were evaluated for relevant information, and data were also obtained from the manufacturer\u2019s website and the package insert. Lenacapavir has been approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistance for whom the current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. It is the first in a new class of drugs called capsid inhibitors to receive FDA approval. Lenacapavir is a long-acting subcutaneous injectable to be administered once every 6 months. The phase 3 clinical trial evaluating lenacapavir has demonstrated its efficacy in viral load reduction from baseline compared to placebo in patients receiving optimized background therapy. The most common adverse events reported in the clinical trial were injection site reactions, occurring in 63% of participants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Lenacapavir is a novel capsid inhibitor indicated, in combination with other antiretroviral therapy, for treatment of multidrug-resistant HIV-1 infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxad223","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T08:45:06Z","timestamp":1695890706000},"page":"1774-1780","source":"Crossref","is-referenced-by-count":17,"title":["Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV"],"prefix":"10.1093","volume":"80","author":[{"given":"Caitlin","family":"Prather","sequence":"first","affiliation":[{"name":"Inova Health System , Fairfax, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lee","sequence":"additional","affiliation":[{"name":"Inova Health System , Fairfax, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolynne","family":"Yen","sequence":"additional","affiliation":[{"name":"Inova Health System , Fairfax, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2023120510405348600_CIT0001","author":"UNAIDS","year":"2023"},{"key":"2023120510405348600_CIT0002","volume-title":"Estimated HIV Incidence and Prevalence in the United States, 2015\u20132019","author":"Centers for Disease Control and Prevention","year":"2021"},{"issue":"6","key":"2023120510405348600_CIT0003","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJM199808063390612","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"339","author":"Michaels","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"2023120510405348600_CIT0004","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.3390\/v6104095","article-title":"Current perspectives on HIV-1 antiretroviral drug resistance","volume":"6","author":"Iyidogan","year":"2014","journal-title":"Viruses"},{"issue":"6","key":"2023120510405348600_CIT0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1368-7646(02)00118-8","article-title":"HIV mutagenesis and the evolution of antiretroviral drug resistance","volume":"5","author":"Mansky","year":"2002","journal-title":"Drug Resist Updat"},{"key":"2023120510405348600_CIT0006","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2023"},{"issue":"8","key":"2023120510405348600_CIT0007","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/aid.2017.0295","article-title":"Changes from 2000 to 2009 in the prevalence of HIV-1 containing drug resistance-associated mutations from antiretroviral therapy-naive, HIV-1-infected patients in the United States","volume":"34","author":"Ross","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"2023120510405348600_CIT0008","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/hiv.13288","article-title":"Opening the door on entry inhibitors in HIV: redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV","volume":"23","author":"Orkin","year":"2022","journal-title":"HIV Med"},{"issue":"4","key":"2023120510405348600_CIT0009","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jmv.21034","article-title":"Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs","volume":"80","author":"Perno","year":"2008","journal-title":"J Med Virol"},{"issue":"1","key":"2023120510405348600_CIT0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"issue":"6","key":"2023120510405348600_CIT0011","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014-2018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023120510405348600_CIT0012","author":"Food and Drug Administration","year":"2022"},{"key":"2023120510405348600_CIT0013","author":"Gilead Sciences","year":"2022"},{"key":"2023120510405348600_CIT0014","article-title":"After overcoming vial issue, Gilead wins FDA approval for long-acting HIV injectable Sunlenca","author":"Becker","year":"2022"},{"key":"2023120510405348600_CIT0015","author":"Sunlenca (lenacapavir)","year":"2023"},{"issue":"1","key":"2023120510405348600_CIT0016","first-page":"15","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Hadas","year":"2022"},{"issue":"2","key":"2023120510405348600_CIT0017","first-page":"100","volume":"11","author":"Rossi","year":"2021","journal-title":"Structure, function, and interactions of the HIV-1 capsid protein. Life"},{"key":"2023120510405348600_CIT0018","article-title":"GS-6207 sustained delivery formulation supports 6-month dosing interval","author":"Begley"},{"key":"2023120510405348600_CIT0019","article-title":"Long-acting lenacapavir in a combination regimen for treatment-naive PWH: week 80","author":"Hagins"},{"key":"2023120510405348600_CIT0020","article-title":"PK, food effect, and safety of oral GS-6207, a novel HIV-1 capsid inhibitor","author":"Begley"},{"issue":"6","key":"2023120510405348600_CIT0021","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/v14061202","article-title":"Drug interactions in lenacapavir-based long-acting antiviral combinations","volume":"14","author":"Cilento","year":"2022","journal-title":"Viruses"},{"issue":"3","key":"2023120510405348600_CIT0022","doi-asserted-by":"crossref","first-page":"e02057","DOI":"10.1128\/AAC.02057-20","article-title":"Absence of lenacapavir (GS-6207) phenotypic resistance in HIV Gag cleavage site mutants and in isolates with resistance to existing drug classes","volume":"65","author":"Margot","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2023120510405348600_CIT0023","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/jac\/dkab503","article-title":"Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study","volume":"77","author":"Margot","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"19","key":"2023120510405348600_CIT0024","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"2023120510405348600_CIT0025","doi-asserted-by":"crossref","first-page":"ofac492.108","DOI":"10.1093\/ofid\/ofac492.108","article-title":"Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: week 52 results","volume":"9","author":"Ogbuagu","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2023120510405348600_CIT0026","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV"},{"key":"2023120510405348600_CIT0027","author":"Gilead Sciences","year":"2022"},{"key":"2023120510405348600_CIT0028","author":"Gilead Sciences","year":"2022"},{"key":"2023120510405348600_CIT0029","author":"Lenacapavir","year":"2020"},{"key":"2023120510405348600_CIT0030","author":"Gilead Sciences","year":"2023"},{"key":"2023120510405348600_CIT0031","author":"Parish","year":"2020"},{"issue":"1","key":"2023120510405348600_CIT0032","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12954-023-00730-z","article-title":"Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and\/or housing instability","volume":"20","author":"Fletcher","year":"2023","journal-title":"Harm Reduct J"},{"issue":"7","key":"2023120510405348600_CIT0033","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s10461-022-03949-2","article-title":"Factors associated with preferences for long-acting injectable antiretroviral therapy among adolescents and young people living with HIV in South Africa","volume":"27","author":"Toska","year":"2023","journal-title":"AIDS Behav"},{"key":"2023120510405348600_CIT0034","author":"Gilead Sciences","year":"2023"},{"key":"2023120510405348600_CIT0035","year":"2023"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad223\/51889094\/zxad223.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/24\/1774\/53979681\/zxad223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/24\/1774\/53979681\/zxad223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T10:41:23Z","timestamp":1701772883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/24\/1774\/7284919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":35,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2023,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad223","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,15]]},"published":{"date-parts":[[2023,9,28]]}}}